Understand the source comparison
PE-22-28 Versus Spadin and Shortened Analogues
Spadin has the clearer peer-reviewed foundation, including published work describing it as a sortilin-derived peptide and TREK-1 blocker with antidepressant-like effects in rodents [1]. PE-22-28 is more narrowly discussed as a shortened spadin-related fragment
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Spadin has the clearer peer-reviewed foundation, including published work describing it as a sortilin-derived peptide and TREK-1 blocker with antidepressant-like effects in rodents [1]. PE-22-28 is more narrowly discussed as a shortened spadin-related fragment or analog, with a thinner publicly visible evidence base under its exact name [2].
- The practical difference is evidence depth. Spadin helps explain why PE-22-28 is scientifically interesting, but PE-22-28 still needs its own identity, pharmacology, dosing, safety, and human-outcome evidence before therapeutic claims can be considered clinically meaningful.